NASDAQ$BMEA
Biomea Fusion Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Reported financial results for the third quarter of 2021.
Biomea Fusion reported a net loss attributable to common stockholders of $12.61 million for the third quarter of 2021. The company's cash, cash equivalents, restricted cash, and investments were $191.9 million as of September 30, 2021. The company also announced FDA clearance of Investigational New Drug Application (IND) for BMF-219.
- Received FDA clearance of IND for BMF-219, an irreversible menin inhibitor for the treatment of relapsed or refractory acute leukemias.
- Initiating a Phase I study for the treatment of relapsed or refractory acute leukemia.
- Conducting preclinical studies to demonstrate the potential for BMF-219 in genetically defined patient subsets of DLBCL and MM.
- Opened Biomea Innovation Research Center to generate a broad portfolio of next generation covalent inhibitors.
Headline financials
Revenue & EPS history
Biomea Fusion · Revenue · Quarterly
$1.07B
Forward guidance
Biomea Fusion expects its cash balance to sustain operations well into 2024 and anticipates announcing the next pipeline candidate in the first half of 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q3 2021
+5.2%
Avg return
Earnings day
+3.3%
Avg return
5 days after
+3.0%
Avg return
30 days after
40%
8 / 20 earnings
Positive
+109.7%
Q4 2022
Best reaction
-16.7%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +15.3% | -13.5% | -23.7% | |
| Q3 2025 | -0.7% | -4.3% | -21.0% | |
| Q2 2025 | +0.6% | -3.2% | +21.5% | |
| Q1 2025 | -1.3% | -4.6% | +73.0% | |
| Q4 2024 | +1.2% | -7.8% | -8.7% | |
| Q3 2024 | -16.7% | -27.2% | -43.4% | |
| Q1 2024 | +6.7% | +3.7% | -9.1% | |
| Q4 2023 | -14.4% | -14.8% | -22.6% | |
| Q3 2023 | -6.8% | -7.9% | +16.3% | |
| Q2 2023 | -2.4% | -9.3% | -22.2% | |
| Q1 2023 | -3.3% | +2.6% | +12.5% | |
| Q4 2022 | +109.7% | +101.0% | +84.6% | |
| Q3 2022 | -15.6% | -29.4% | -43.3% | |
| Q2 2022 | +3.3% | +11.8% | +8.5% | |
| Q1 2022 | +35.2% | +69.4% | +127.2% | |
| Q4 2021 | -13.8% | -7.7% | -36.2% | |
| Q3 2021 | +7.6% | +2.0% | -7.9% | |
| Q2 2021 | -0.6% | -11.0% | -3.4% | |
| Q1 2021 | -0.3% | +7.9% | -21.4% | |
| Q4 2020 | -0.3% | +7.9% | -21.4% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro